Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to $7.9 million.

  • Traws Pharma's Total Liabilities fell 2799.71% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year decrease of 2799.71%. This contributed to the annual value of $56.6 million for FY2024, which is 37116.81% up from last year.
  • Latest data reveals that Traws Pharma reported Total Liabilities of $7.9 million as of Q3 2025, which was down 2799.71% from $7.4 million recorded in Q2 2025.
  • Traws Pharma's 5-year Total Liabilities high stood at $56.6 million for Q4 2024, and its period low was $7.4 million during Q2 2025.
  • In the last 5 years, Traws Pharma's Total Liabilities had a median value of $11.4 million in 2021 and averaged $13.3 million.
  • As far as peak fluctuations go, Traws Pharma's Total Liabilities surged by 37116.81% in 2024, and later tumbled by 4152.7% in 2025.
  • Traws Pharma's Total Liabilities (Quarter) stood at $9.4 million in 2021, then rose by 18.22% to $11.1 million in 2022, then increased by 8.57% to $12.0 million in 2023, then skyrocketed by 371.17% to $56.6 million in 2024, then tumbled by 86.04% to $7.9 million in 2025.
  • Its last three reported values are $7.9 million in Q3 2025, $7.4 million for Q2 2025, and $13.1 million during Q1 2025.